PDCD1 and melanoma: CD14+CD16−CD33+HLA-DRhi monocytes were found to predict response to anti-PD-1 therapy in melanoma, supporting the findings that this subpopulation of monocytes has a role in anti-tumor activity and to those potential mechanisms of therapeutic efficacy, and their analysis as mechanisms of resistance.27